TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31764363

Group type: EXPERIMENTAL
Intervention: Perioperative intravenous dexamethasone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 64
Study: 28985960

Group type: EXPERIMENTAL
Intervention: Selumetinib 75mg (3 × 25 mg) Phase II capsules
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Selumetinib 75mg (3 × 25 mg) Phase III capsules
Number of subjects: 61
Study: 26795265

Group type: EXPERIMENTAL
Intervention: Combined dietary supplement (2 capsules/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined dietary supplement (10 or 50 mg/kg orally)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (2% DMSO)
Number of subjects: 40
Study: 24070494

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 μg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 μg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Salmeterol xinafoate (SLM) 50 μg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination FP 100 μg + SLM 50 μg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salmeterol (SLM) 10(‐8) mol/L with Fluticasone (FP) 10(‐9) mol/L
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salmeterol (SLM) 10(‐9) mol/L with Fluticasone (FP) 10(‐11) mol/L
Number of subjects: 8
Study: 21795438

Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR) measured in obese pregnant women
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metabolic cost of walking measured in obese pregnant women
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Self-selected walking (SSW) speed measured in obese pregnant women
Number of subjects: 23

Group type: COMPARATOR
Intervention: RMR measured in nonpregnant control subjects
Number of subjects: 23
Study: 20003200

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (Group 1; blood glucose concentration 4.4‐6.1 mmol/l)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional insulin treatment (Group 2; blood glucose level 7.0 mmol/l‐11.0 mmol/l)
Number of subjects: 29
Study: 17972479

Group type: EXPERIMENTAL
Intervention: Monocular viewing during absolute-direction judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binocular viewing during absolute-direction judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative-direction judgments
Number of subjects: 0
Study: 15165649

Group type: EXPERIMENTAL
Intervention: Nocturnal hot flashes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nights with hot flashes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall association of hot flashes
Number of subjects: 24
Study: 11564247

Group type: EXPERIMENTAL
Intervention: High-dose mannitol (HDM)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conventional-dose mannitol
Number of subjects: 178
Study: 9640184

Group type: EXPERIMENTAL
Intervention: Closed eye soft contact lens wear
Number of subjects: 32

Group type: COMPARATOR
Intervention: No contact lens wear (control)
Number of subjects: 32
Study: 8010782

Group type: EXPERIMENTAL
Intervention: HeartMate 1000 IP LVAD
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no LVAD)
Number of subjects: 19
Study: 2510282

Group type: EXPERIMENTAL
Intervention: Rioprostil (600 micrograms, single oral dose)
Number of subjects: 4
Study: 31944277

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel 0.05%
Number of subjects: 16
Study: 31192478

Group type: EXPERIMENTAL
Intervention: Breathing-based walking intervention for two months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 28449910

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (bi-weekly educational classes)
Number of subjects: 46
Study: 25287166

Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract containing sulforaphane (BSES) in group A (H. pylori (+))
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract containing sulforaphane (BSES) in group C (H. pylori (-))
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo in group B (H. pylori (+))
Number of subjects: 89
Study: 23545466

Group type: EXPERIMENTAL
Intervention: Paro robot intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resident dog
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paro robot
Number of subjects: 40
Study: 21640556

Group type: EXPERIMENTAL
Intervention: Home-based disease management arm receiving comprehensive advice and counseling by visiting nurses for 2 months followed by telephone follow-up for 4 months.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 156
Study: 18952612

Group type: EXPERIMENTAL
Intervention: Diesel exhaust inhalation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 20
Study: 16344851

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation with manual respiratory kinesitherapy (inhale and exhale pressure between 15 cm H(2)O and 45 cm H(2)O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual kinesitherapy
Number of subjects: 0
Study: 12539807

Group type: COMPARATOR
Intervention: External cardioversion (EC, n = 27)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Internal cardioversion (IC, n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: External cardioversion (EC)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Internal cardioversion (IC)
Number of subjects: 55
Study: 11000660

Group type: EXPERIMENTAL
Intervention: Oral clonidine 150 micrograms
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (oral antacid, alugel hydroxide 300 mg)
Number of subjects: 110
Study: 8968266

Group type: EXPERIMENTAL
Intervention: Serum IGF-binding protein-3 concentrations in women
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serum IGF-binding protein-3 concentrations in men
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serum IGF-binding protein-3 concentrations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 concentrations
Number of subjects: 108
Study: 1515211

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF) 10 micrograms/m2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN gamma) 10 micrograms/m2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both TNF and IFN gamma
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 7198209

Group type: EXPERIMENTAL
Intervention: Lecithin (10 gm three times daily for 3 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (10 gm three times daily for 3 months)
Number of subjects: 11
Study: 31626213

Group type: EXPERIMENTAL
Intervention: Elastic kinesiotaping
Number of subjects: 65

Group type: COMPARATOR
Intervention: Medical non-elastic hypoallergenic patch (placebo)
Number of subjects: 65
Study: 28244946

Group type: EXPERIMENTAL
Intervention: Laryngoscope-Assisted Lightwand Intubation (LALI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Lightwand Intubation (CLI)
Number of subjects: 20
Study: 24943808

Group type: EXPERIMENTAL
Intervention: Maternal use of any antibiotics during pregnancy
Number of subjects: 6690

Group type: EXPERIMENTAL
Intervention: Maternal use of cephalosporins during pregnancy
Number of subjects: 6690

Group type: EXPERIMENTAL
Intervention: Child's use of antibiotics during the first year of life
Number of subjects: 6690

Group type: EXPERIMENTAL
Intervention: Child's use of cephalosporins
Number of subjects: 6690

Group type: EXPERIMENTAL
Intervention: Child's use of sulphonamides and trimethoprim
Number of subjects: 6690

Group type: EXPERIMENTAL
Intervention: Child's use of macrolides
Number of subjects: 6690

Group type: EXPERIMENTAL
Intervention: Child's use of amoxicillin
Number of subjects: 6690
Study: 24120933

Group type: EXPERIMENTAL
Intervention: multi-component intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: usual care comparison group
Number of subjects: 500
Study: 21344494

Group type: EXPERIMENTAL
Intervention: Additive tolterodine extended release (ER) 4 mg q.d.
Number of subjects: 137

Group type: COMPARATOR
Intervention: No tolterodine ER (Control group)
Number of subjects: 137
Study: 19228442

Group type: EXPERIMENTAL
Intervention: Iterative lesson sequence (cycling between concept and procedure lessons)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Concepts-first condition (all concept lessons presented before procedure lessons)
Number of subjects: 103
Study: 17583187

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg once daily, with dosage adjustment to 16 mg if BP was not normalized
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC)
Number of subjects: 702
Study: 15612963

Group type: EXPERIMENTAL
Intervention: Long-acting beta-agonist (LABA) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Increased doses of inhaled corticosteroid (ICS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inhaled corticosteroid (ICS) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Baseline BAL eotaxin levels in asthmatics
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 3 months of treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison with non-asthmatic controls
Number of subjects: 70
Study: 12377957

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: XRT and placebo
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: XRT and TAM
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Distant treatment failures
Number of subjects: 1009
Study: 9718910

Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation for 6 weeks
Number of subjects: 15
Study: 8592764

Group type: EXPERIMENTAL
Intervention: NANP vaccine
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 2767067

Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.300 g.kg‐1 body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium chloride placebo (0.045 g.kg‐1 body mass)
Number of subjects: 9
Study: 603002

Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Alphaxalone/alphadalone (0.036 ml/kg)
Number of subjects: 31
Study: 30513445

Group type: EXPERIMENTAL
Intervention: Prenatal web-based breastfeeding education program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 112
Study: 29027653

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg kg⁻¹
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 1 µg kg⁻¹
Number of subjects: 60
Study: 26176646

Group type: EXPERIMENTAL
Intervention: Telemedicine relapse prevention programme ITAREPS (active group)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: ITAREPS-related variables
Number of subjects: 146
Study: 23497404

Group type: EXPERIMENTAL
Intervention: Intervention targeting frailty characteristics
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (usual health care and support services)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Intervention and Control groups
Number of subjects: 216
Study: 21663722

Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bone-patellar tendon (BPT)
Number of subjects: 62
Study: 20214329

Group type: EXPERIMENTAL
Intervention: Puerarin preconditioning (0.6 g in 250 mL 5% glucose solution for intravenous dripping every day for one week before operation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 17612909

Group type: EXPERIMENTAL
Intervention: Perindopril (ACE inhibitor)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atenolol (beta-blocker)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy normotensive controls
Number of subjects: 31
Study: 15062889

Group type: EXPERIMENTAL
Intervention: telmisartan (40 to 80 mg once daily)
Number of subjects: 490

Group type: COMPARATOR
Intervention: valsartan (80 to 160 mg once daily)
Number of subjects: 490
Study: 11906768

Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Number of subjects: 105

Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 105
Study: 9846854

Group type: EXPERIMENTAL
Intervention: Oxamniquine treatment
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 8005825

Group type: EXPERIMENTAL
Intervention: Etanidazole (ETA) with accelerated fractionation XRT 20 Gy BID to 40 Gy in 2 weeks and continuous infusion during brachytherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Etanidazole (ETA) with accelerated fractionation XRT 2 Gy BID to 40 Gy in 2 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Etanidazole (ETA) with accelerated fractionation XRT 2 Gy BID to 40 Gy in 2 weeks without a 2-week break
Number of subjects: 70
Study: 2551469

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg by metered dose inhaler twice a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 54639

Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 8
Study: 31303567

Group type: EXPERIMENTAL
Intervention: Citalopram (n=744)
Number of subjects: 8262

Group type: EXPERIMENTAL
Intervention: Paroxetine (n=2981)
Number of subjects: 8262

Group type: EXPERIMENTAL
Intervention: Sertraline (n=1202)
Number of subjects: 8262

Group type: COMPARATOR
Intervention: Fluoxetine (active-control group; n=754)
Number of subjects: 8262

Group type: COMPARATOR
Intervention: Placebo (n=2581)
Number of subjects: 8262

Group type: EXPERIMENTAL
Intervention: SSRIs (overall)
Number of subjects: 8262
Study: 30527258

Group type: EXPERIMENTAL
Intervention: 25 g Resistant Maltodextrin (RMD)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 15 g Resistant Maltodextrin (RMD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0 g Resistant Maltodextrin (RMD)
Number of subjects: 51
Study: 27250715

Group type: EXPERIMENTAL
Intervention: Strength training associated with active LLLT (808 nm, 100 mW, 7 J)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Strength training associated with placebo LLLT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Strength training associated with active LLLT (TLG)
Number of subjects: 48
Study: 25139426

Group type: EXPERIMENTAL
Intervention: Cooked white rice with high β-glucan barley (BAR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 21
Study: 22849533

Group type: EXPERIMENTAL
Intervention: Aripiprazole (average final dose 7.8 mg/day, range 2.5-15 mg/day)
Number of subjects: 25
Study: 20026576

Group type: EXPERIMENTAL
Intervention: Therapy focused on familiarizing patients with communicative functions of gestures and improving spatial precision of gestures
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (ten patients tested repeatedly without interpolated therapy)
Number of subjects: 23
Study: 17548730

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 160
Study: 15876309

Group type: EXPERIMENTAL
Intervention: Levocetirizine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 12235650

Group type: EXPERIMENTAL
Intervention: Individual support (IS) including nutritional support
Number of subjects: 137

Group type: COMPARATOR
Intervention: Group rehabilitation (GR)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: IS + GR (ISGR)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 137
Study: 10098759

Group type: EXPERIMENTAL
Intervention: Chemotherapy (alternating courses of etoposide‐carboplatin and etoposide‐ifosfamide for a total of four courses) + 40 Gy local irradiation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Craniospinal radiotherapy (for metastatic patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall treatment (combination of chemotherapy and local radiotherapy)
Number of subjects: 57
Study: 7596370

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy (prednisone with either cyclosporine or azathioprine) for 24 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 111
Study: 2403792

Group type: EXPERIMENTAL
Intervention: Intramyometrial carboprost tromethamine (125 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramyometrial oxytocin (20 U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (oxytocin)
Number of subjects: 0
Study: 9111

Group type: EXPERIMENTAL
Intervention: 1.5 mg bromazepam p.o.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31033512

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation with heparin (target activated partial thromboplastin time between 50 and 70 s)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lower dose heparin (up to 12,000 U/24 hr aiming for activated partial thromboplastin time < 45 s)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation with heparin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lower dose heparin
Number of subjects: 32
Study: 29045553

Group type: EXPERIMENTAL
Intervention: S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1154
Study: 25957650

Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional hip arthroplasty
Number of subjects: 38
Study: 23589097

Group type: EXPERIMENTAL
Intervention: Tailored home‐based exercise (HE; 1‐hour training), twice a week for 1 year
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Group‐based exercise (GE; 4‐hour sessions with approximately 1‐hour training), twice a week for 1 year
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (CG) receiving the usual community care
Number of subjects: 210
Study: 21159803

Group type: EXPERIMENTAL
Intervention: 150 ml of intravenous contrast at a rate of 2.5 ml s(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 ml of intravenous contrast at a rate of 2 ml s(‐1)
Number of subjects: 40
Study: 19909549

Group type: EXPERIMENTAL
Intervention: Information technology‐assisted self‐management
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Care management by a dietitian and exercise counselor
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 17023283

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lateral decubitus position
Number of subjects: 41
Study: 12949996

Group type: EXPERIMENTAL
Intervention: Gepirone immediate-release (gepirone-IR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gepirone extended-release (gepirone-ER, types 1, 2, and 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gepirone extended-release (gepirone-ER)
Number of subjects: 0
Study: 10791521

Group type: COMPARATOR
Intervention: Poractant alfa
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pumactant
Number of subjects: 212
Study: 9493922

Group type: EXPERIMENTAL
Intervention: Home polysomnographic studies
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Laboratory polysomnographic studies
Number of subjects: 64
Study: 8150761

Group type: EXPERIMENTAL
Intervention: Cefepime 2.0 g bd i.v.
Number of subjects: 348

Group type: COMPARATOR
Intervention: Ceftazidime 2.0 g tid i.v.
Number of subjects: 348
Study: 3079597

Group type: EXPERIMENTAL
Intervention: 25 ng/kg GnRH
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 ng/kg GnRH
Number of subjects: 18
Study: 29182426

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) performed two times per week (G2X)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) performed three times per week (G3X)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both G2X and G3X
Number of subjects: 39
Study: 27248138

Group type: EXPERIMENTAL
Intervention: Fasting session (FS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control session (CS)
Number of subjects: 21
Study: 26161469

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 23718760

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: General Psychiatric Management (GPM)
Number of subjects: 180
Study: 20409606

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg daily
Number of subjects: 167
Study: 18431235

Group type: EXPERIMENTAL
Intervention: Folic acid therapy (15 mg/day of methyltertrahydrofolate for 1 year)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Folic acid therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Folic acid therapy in high-risk subgroup (older recipients and those with coronary artery disease)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Folic acid therapy in lower-risk subgroup
Number of subjects: 51
Study: 16644433

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging
Number of subjects: 40
Study: 12718214

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (20 mg/day for 20 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inhaled benacort (400 micrograms twice a day for 20 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 40
Study: 10692234

Group type: EXPERIMENTAL
Intervention: HAART plus IL-2
Number of subjects: 22

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 22